Ulcerative Colitis – Unmet Need – Unmet Need – Moderate to Severe Ulcerative Colitis (US/EU)

The treatment landscape for ulcerative colitis (UC) is rapidly evolving. TNF-alpha inhibitors (Johnson & Johnson Innovative Medicine’s Remicade, AbbVie’s Humira), a CAM inhibitor (Takeda’s Entyvio), and an IL-12/23 inhibitor (Johnson & Johnson Innovative Medicine’s Stelara) are the mainstays of treatment for moderate to severe UC. However, these agents have safety risks and efficacy limitations. Newer alternatives, such as a JAK inhibitor (AbbVie’s Rinvoq), IL-23 inhibitors (Eli Lilly’s Omvoh, AbbVie’s Skyrizi, and Johnson & Johnson Innovative Medicine’s Tremfya), and S1P-R modulators (BMS’s Zeposia and Pfizer’s Velsipity) have expanded the treatment options, but a significant unmet need remains for patients whose UC is refractory to these therapies. Emerging agents with novel mechanisms of action—including anti-TL1A therapies and next-generation small molecules—offer potential breakthroughs, but their long-term efficacy, safety, and positioning within the treatment paradigm remain to be seen.

Questions answered

• What are the treatment drivers and goals in moderate to severe UC?
• How do current therapies perform on treatment drivers and goals for moderate to severe UC?
• In addition to efficacy, which drug attributes most strongly influence physician prescribing behaviors, and which have a limited impact?
• What are the prevailing areas of unmet need and hidden opportunity in the treatment of moderate to severe UC?
• What trade-offs across clinical attributes and prices are acceptable to U.S. and European gastroenterologists for a hypothetical new UC drug?

Markets covered: United States, United Kingdom, France, Germany

Primary research: Survey of 61 U.S. and 32 European gastroenterologists, fielded in April 2026

Key companies: AbbVie, Johnson & Johnson Innovative Medicine, Pfizer, Takeda, Eli Lilly, BMS

Key drugs: Humira and biosimilars, Remicade and biosimilars, Entyvio, Stelara, Omvoh, Skyrizi, Tremfya, Rinvoq, Zeposia, Velsipity

Product description

Unmet Need offers insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities, enabling you to:

• Evaluate clinical and nonclinical product attributes that influence treatment decisions through physicians’ weightings and analysis of stated vs. derived importance.
• Pinpoint areas of high unmet need by assessing current drug performance against key attributes and treatment drivers.
• Analyze market scenarios for different target product profiles using the TPP Simulator.

Key feature

Target Product Profile (TPP) simulator tool allows for customizable market simulations based on conjoint analysis. Compare up to seven TPPs across multiple disease-specific attributes and price points to gauge which variables influence prescribing behavior.